Canaccord Genuity analysts set a $37 price target on Insulet Corp. stock, dailypolitical.com reported. The firm currently rates the stock a “buy.” “Management has positively commented . . . that new patient growth remains robust,” analysts wrote. In the most recent quarter, revenue rose 20 percent, compared to the same quarter last year. Bedford-based Insulet makes the OmniPod Insulin Management System for people with insulin-dependent diabetes.